Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of VX-548 with Omeprazole and Rifampin in Healthy Subjects
NCT05635110Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of suzetrigine in pain (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration at Day 28 and Area Under the Concentration Versus Time Curve From Time Zero Extrapolated to Infinity at Day 28. Started Dec 2022; status: completed.
02
Drugs
suzetrigine
03
Conditions
pain
Beyond the preview
Go deeper on NCT05635110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05635110.